PB1938: 4WHIM: EVALUATING MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, IN PATIENTS WITH WHIM SYNDROME VIA A GLOBAL PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH OPEN-LABEL EXTENSION

Bibliographic Details
Main Authors:	D. C. Dale, L. Alsina, A. Azar, R. Badolato, Y. Bertrand, A. Deya, K. E. Dickerson, N. Ezra, H. Hasle, H. J. Kang, S. Kiani-Alikhan, T. Kuijpers, A. Kulagin, D. Langguth, C. Levin, O. Neth, J. Peake, C. E. Rutten, A. Shcherbina, T. K. Tarrant, M. G. Vossen, C. A. Wysocki, A. Belschner, D. Cadavid, Y. Hu, H. Jiang, R. MacLeod, W. Tang, M. Tillinger, J. Donadieu
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000850592.82147.9b

Internet